Home

Phillip B. Donenberg

CIK 1238120 · SVP and CFO · last filed 2026-06-12

Phillip B. Donenberg is a SVP and CFO who has filed 42 SEC Form 4 insider transactions across 8 companies since 2007. The most recent filing, for SNSE, was dated Jun 12, 2026. Across all open-market trades the lifetime net is +$161.7K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $1.5M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.54M

Companies

8

Total Filings

42

Lifetime Open-Market Net

$161.7K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Sensei Biotherapeutics, Inc. (SNSE) Delisted Director — $13.85 — $0 3 2026-06-12
TECX Director — $32.71 — $0 2 2026-06-10
TSHA Director 241,289 $6.37 $1.54M $123.3K 9 2026-06-02
Tectonic Therapeutic, Inc. (AVRO) Delisted Director 167 $16.80 $2.8K $23.4K 7 2023-06-08
Assertio Therapeutics, Inc (DEPO) Delisted SVP and CFO — — — $0 1 2018-07-16
AveXis, Inc. (AVXS) Delisted Chief Financial Officer 3,800 — — $0 3 2018-05-15
ANI PHARMACEUTICALS INC (BPAX) Delisted Sr VP of Finance, CFO, Secy 7,387 — — $14.9K 13 2012-01-27
ANI PHARMACEUTICALS INC (BPA) Delisted CFO, Treasurer and Secretary 35,822 — — $0 2 2007-02-21

Recent Filings

42 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-12 Sensei Biotherapeutics, Inc. (SNSE) Delisted Grant (A) — $0 EDGAR
2026-06-10 TECX Grant (A) — $0 EDGAR
2026-06-02 TSHA Grant (A) +21,335 $0 EDGAR
2026-04-14 Sensei Biotherapeutics, Inc. (SNSE) Delisted Grant (A) — $0 EDGAR
2026-02-17 Sensei Biotherapeutics, Inc. (SNSE) Delisted Grant (A) — $0 EDGAR
2025-06-11 TECX Grant (A) — $0 EDGAR
2025-06-04 TSHA Grant (A) +56,623 $0 EDGAR
2024-06-24 — Grant (A) — $0
2024-05-31 TSHA Grant (A) +49,220 $0 EDGAR
2023-08-16 TSHA Buy (P) +111,111 $100.0K EDGAR
Showing 1–10 of 42
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.